When was 4D Molecular Therapeutics founded?

4D Molecular Therapeutics was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Where is 4D Molecular Therapeutics located?

4D Molecular Therapeutics is headquartered in Emeryville, United States.

How many employees does 4D Molecular Therapeutics have?

As of Aug 31, 2026, the latest employee count at 4D Molecular Therapeutics is 218.

Is 4D Molecular Therapeutics a funded company?

4D Molecular Therapeutics is a funded company, having raised a total of $187M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 12, 2015.

When was the latest funding round of 4D Molecular Therapeutics?

4D Molecular Therapeutics' latest funding was a $***** Series C round on Jun 16, 2020, with participation from 16 investors.

What is the annual revenue of 4D Molecular Therapeutics?

Annual revenue of 4D Molecular Therapeutics is between $50M and $100M as on Dec 31, 2025

Where does 4D Molecular Therapeutics rank among its competitors?

4D Molecular Therapeutics ranks 1st amongst 171 active competitors, of which 60 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Kala Pharmaceuticals, which secured $1.75M in Mar, 2026.

Who are the top competitors of 4D Molecular Therapeutics?

4D Molecular Therapeutics' top competitors include Regenxbio, CureVac and Kala Pharmaceuticals. Among them, Kala Pharmaceuticals secured the most recent funding round in March, 2026.

4D Molecular Therapeutics - 2026 Company Profile, Funding, Competitors & Financials

4D Molecular Therapeutics is a public company based in Emeryville (United States), founded in 2013. It operates as a Developer of gene therapeutics for genetic disorders. 4D Molecular Therapeutics has raised $187M in funding from Viking Global Investors. The company has 171 active competitors, including 60 funded and 33 that have exited. Its top competitors include companies like Regenxbio, CureVac and Kala Pharmaceuticals.

Company Details

4d Molecular Therapeutics researchers develop gene therapy products for severe genetic diseases involving a diverse array of target tissues, including the following areas: retina, heart, liver, brain (CNS), skeletal muscle, and lung. The company uses Directed Vector Evolution, a vector discovery platform to create customized gene delivery vehicles to deliver genes to any tissue or organ in the body.

Key Metrics

Founded Year

2013

Location

Emeryville, United States

Stage

Public

Total Funding

$187M in 6 rounds

Latest Funding Round

Series C, Jun 16, 2020, $*****

Investors

Viking Global Investors & 19 more

Ranked

1^st among 171 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

218 as on Aug 31, 2026

Similar Companies

Regenxbio & 177 more

Exit Details

Public

View 4D Molecular Therapeutics' full profile

4D Molecular Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
4D MOLECULAR THERAPEUTICS, INC. CIN: 1650648 , United States, Active	Mar 10, 2015	$50M - $100M (As on Dec 31, 2025)	-	-
4d Molecular Therapeutics, Inc. CIN: 47-3506994 , United States, Active	Mar 10, 2015	-	147 (As on Dec 31, 2023)	-

4D Molecular Therapeutics got listed on Dec 11, 2020.

Click here to take a look at 4D Molecular Therapeutics's IPO in detail

4D Molecular Therapeutics has raised a total funding of $187M over 6 rounds. Its first funding round was on Aug 12, 2015. Its latest funding round was a Series C round on Jun 16, 2020 for $*****. 16 investors participated in its latest round. 4D Molecular Therapeutics has 20 institutional investors.

Here is the list of recent funding rounds of 4D Molecular Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 16, 2020	3280819	Series C	9997668	7969311	9903064	7140565
Sep 05, 2018	8648456	Series B	8399688	8771225	8759257	Janus Henderson Investors & 10 more
Sep 19, 2017	2638656	Series A	1058035	9660035	1438744	Cystic Fibrosis Foundation

Access funding benchmarks and valuations. Sign up today!

View details of 4D Molecular Therapeutics's funding rounds and investors

4D Molecular Therapeutics' employee count trend

4D Molecular Therapeutics has 218 employees as of Aug 26. Here is 4D Molecular Therapeutics's employee count trend over the years:

Employee count trend for 4D Molecular Therapeutics

Uncover 4D Molecular Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 4D Molecular Therapeutics include Regenxbio, CureVac and Kala Pharmaceuticals. Here is the list of Top 10 competitors of 4D Molecular Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	BVF Partners, ArrowMark Partners & 18 others	67/100
2nd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
3rd	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
4th	Kala Pharmaceuticals 2009, Waltham (United States), Public	Developer of ophthalmic treatments based on its mucosal penetrating product platform	$115M	Polaris Partners, Lux Capital & 17 others	66/100
5th	PureTech Health 2005, Boston (United States), Public	Developer of immunotherapeutics for multiple diseases	$107M	Vitruvian Partners, Invesco Perpetual & 1 others	66/100
6th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, ATW Partners & 6 others	65/100
7th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Lincoln Park Capital & 8 others	64/100
8th	Kriya Therapeutics 2012, Redwood City (United States), Series D	Developer of therapeutic solutions for the treatment of diabetes	$938M	Patient Square Capital, Foresite Capital ... & 16 others	64/100
9th	AAVantgarde Bio 2021, Milano (Italy), Series B	Developer of gene therapies using Adeno-Associated Viral vectors	$206M	Atlas Venture, Forbion & 11 others	63/100
10th	Variant Bio 2018, Brooklyn (United States), Series B	Developer of therapeutics for the treatment of orphan indications	$128M	Lux Capital, SoftBank Vision Fund & 4 others	62/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on 4D Molecular Therapeutics's competitors? Click here to see the top ones

4D Molecular Therapeutics has made no investments or acquisitions yet.

Here is the latest report on 4D Molecular Therapeutics's sector:

Free

Ophthalmology - Sector Report

Edition: August, 2026 (68 Pages)

View all reports related to 4D Molecular Therapeutics

Media has covered 4D Molecular Therapeutics for a total of 19 events in the last 1 year, 6 of them have been about company updates and 5 about people movement.